Proton therapy for pediatric and adolescent esthesioneuroblastoma

Pediatric Blood and Cancer

Volumn 62, Issue 9, 2015, Pages 1523-1528

  Lucas, John T ^a   Ladra, Matthew M ^b   Macdonald, Shannon M ^c   Busse, Paul M ^c   Friedmann, Alison M ^d   Ebb, David H ^d   Marcus, Karen J ^e   Tarbell, Nancy J ^c   Yock, Torunn I ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Provision Center for Proton Therapy   (United States)

^c Department of Radiation Oncology ^*  (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Esthesioneuroblastoma; Olfactory neuroblastoma; Proton radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL ARTICLE; ENDOCRINE DISEASE; EPISTAXIS; ESTHESIONEUROBLASTOMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; INDUCTION CHEMOTHERAPY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; ODYNOPHAGIA; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DERMATITIS; RADIATION DOSE DISTRIBUTION; RETINOPATHY; RETROSPECTIVE STUDY; RHINITIS; SCHOOL CHILD; SINUSITIS; TREATMENT FAILURE; TREATMENT RESPONSE; XEROSTOMIA; YOUNG ADULT; ADJUVANT THERAPY; ADVERSE EFFECTS; BRAIN TUMOR; COMPUTER ASSISTED RADIOTHERAPY; ESTHESIONEUROBLASTOMA, OLFACTORY; KAPLAN MEIER METHOD; MENINGIOMA; NOSE CAVITY; NOSE NEOPLASMS; PATHOLOGY; RADIATION DOSE; RADIATION INJURIES; SECONDARY; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTHESIONEUROBLASTOMA, OLFACTORY; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MENINGEAL NEOPLASMS; NASAL CAVITY; NOSE NEOPLASMS; PROTON THERAPY; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TOPOTECAN; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84938153362     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25494     Document Type: Article

References (43)

1. Holsinger FC, Hafemeister AC, Hicks MJ, Sulek M, Huh WW, Friedman EM. Differential diagnosis of pediatric tumors of the nasal cavity and paranasal sinuses: A 45-year multi-institutional review. Ear Nose Throat J 2010; 89:534-540.
2. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: A meta-analysis and review. Lancet Oncol 2001; 2:683-690.
3. Yock TI, Caruso PA. Risk of second cancers after photon and proton radiotherapy: A review of the data. Health Phys 2012; 103:577-585.
4. Berger RL, Luc R. Olfactif esthesioneuroblastome. Bull Assoc Fr Etude Cancer 1924; 13:410-420.
5. Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: A general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997; 17:2683-2706.
6. El Kababri M, Habrand JL, Valteau-Couanet D, Gaspar N, Dufour C, Oberlin O. Esthesioneuroblastoma in children and adolescent: Experience on 11 cases with literature review. J Pediatr Hematol Oncol 2014; 36:91-95.
7. Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997; 17:2683-2706.
8. Kumar M, Fallon RJ, Hill JS, Davis MM. Esthesioneuroblastoma in children. J Pediatr Hematol Oncol 2002; 24:482-487.
9. Eich HT, Muller RP, Micke O, Kocher M, Berthold F, Hero B. Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment? Strahlentherapie Onkol 2005; 181:378-384.
10. Gruber GN, Laedrach K, Baumert B, Caversaccio M, Raveh J, Greiner R. Esthesioneuroblastoma: Irradiation alone and surgery alone are not enough. In J Radiat Oncol Biol Phys 2002; 54:486-491.
11. Kuhlthau KA, Pulsifer M, Delahaye J, MacDonald SM, Tarbell NJ, Yock TI. Health-related quality of life of pediatric brain tumor patients on proton treatment. Neuro-Oncology 2010; 12:II111-II111.
12. Pulsifer MB, Delgado I, Tarbell N, Kuhlthau K, MacDonald SM, Yock TI. Neurocognitive outcomes after proton radiation for pediatric brain tumors. J Clin Oncol 2010; 28:1.
13. Arvold ND, Lessell S, Rizzo JF, Licbsch NJ, Yock TI, Loeffler JS, Shih HA. Visual outcome and tumor control following conformal radiotherapy for patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys 2007; 69:S256-S257.
14. Paganetti H, Athar BS, Moteabbed M, Adams JA, Schneider U, Yock TI. Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field. Phys Med Biol 2012; 57:6047-6061.
15. Kuhlthau KA, Pulsifer MB, Yeap BY, Morales DR, Delahaye J, Hill KS, Ebb D, Abrams AN, MacDonald SM, Tarbell NJ, Yock TI. Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. J Clin Oncol 2012; 30:2079-2086.
16. Hall EJ, Wuu CS. Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56:83-88.
17. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006; 65:1-7.
18. Probert JC, Parker BR. Effects of radiation-therapy on bone-growth. Radiology 1975; 114:155-162.
19. Hartley KA, Li C, Laningham FH, Xiong X, Merchant TE. Vertebral body growth after craniospinal irradiation. Int J Radiat Oncol Biol Phys 2008; 70:1343-1349.
20. Fitzek MM, Linggood RM, Adams J, Munzenrider JE. Combined proton and photon irradiation for craniopharyngioma: Long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. Int J Radiat Oncol Biol Phys 2006; 64:1348-1354.
21. Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 2013; 87:46-52.
22. Bhat SR, Goodwin TL, Burwinkle TM, Lansdale MF, Dahl GV, Huhn SL, Gibbs IC, Donaldson SS, Rosenblum RK, Varni JW, Fisher PG. Profile of daily life in children with brain tumors: An assessment of health-related quality of life. J Clin Oncol 2005; 23:5493-5500.
23. Childs SK, Kozak KR, Friedmann AM, Yeap BY, Adams J, MacDonald SM, Liebsch NJ, Tarbell NJ, Yock TI. Proton radiotherapy for parameningeal rhabdomyosarcoma: Clinical outcomes and late effects. Int J Radiat Oncol Biol Phys 2012; 82:635-642.
24. Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, McIntyre J, Adams J, Rosenthal S, Joseph M, Amrein P. Neuroendocrine tumors of the sinonasal tract-Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 2002; 94:2623-2634.
25. Cotter SE, McBride SM, Yock TI. Proton radiotherapy for solid tumors of childhood. Technol Cancer Res Treat 2012; 11:267-278.
26. Gibbs IC, Tuamokumo N, Yock TI. Role of radiation therapy in pediatric cancer. Hematol Oncol Clin North Am 2006; 20:455-470.
27. Hyams VJ, Batsakis JG, Michaels L, editor. Tumors of the upper respiratory tract and ear. 1988. 240-248 p.
28. Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma-clinical analysis of 17 cases. Cancer 1976; 37:1571-1576.
29. Paganetti H, Niemierko A, Ancukiewicz M, Gerweck LE, Goitein M, Loeffler JS, Suit HD. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys 2002; 53:407-421.
30. Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, Jane JA, Levine PA. Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch otolaryngol Head Neck Surg 2006; 132:134-138.
31. Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B, Azria D, Roelandts M, Kaanders JH, Cengiz M, Krengli M, Matzinger O, Zouhair A. Outcome and prognostic factors in olfactory neuroblastoma: A rare cancer network study. Int J Radiat Oncol Biol Phys 2010; 78:992-997.
32. Bachar G, Goldstein DP, Shah M, Tandon A, Ringash J, Pond G, Gullane PJ, Perez-Ordonez B, Gilbert RW, Brown DH, Gentili F, O'Sullivan B, Irish JC. Esthesioneuroblastoma: The Princess Margaret Hospital experience. Head Neck 2008; 30:1607-1614.
33. Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, Jane JA, Levine PA. Esthesioneuroblastoma-Continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg 2006; 132:134-138.
34. Spaulding CA, Kranyak MS, Constable WC, Stewart FM. Esthesioneuroblastoma: A comparison of two treatment eras. Int J Radiat Oncol Biol Phys 1988; 15:581-590.
35. Davis RE, Weissler MC. Esthesioneuroblastoma and neck metastasis. Head Neck 1992; 14:477-482.
36. Maroldi R, Ravanelli M, Borghesi A, Farina D. Paranasal sinus imaging. Eur J Radiol 2008; 66:372-386.
37. Elkon D, Hightower SI, Lim ML, Cantrell RW, Constable WC. Esthesioneuroblastoma. Cancer 1979; 44:1087-1094.
38. Demiroz C, Gutfeld O, Aboziada M, Brown D, Marentette LJ, Eisbruch A. Esthesioneuroblastoma: Is there a need for elective neck treatment? Int J Radiat Oncol Biol Phys 2011; 81:e255-e261.
39. Gore MR, Zanation AM. Salvage treatment of local recurrence in esthesioneuroblastoma: A meta-analysis. Skull Base 2011; 21:1-6.
40. Van Gompel JJ, Carlson ML, Pollock BE, Moore EJ, Foote RL, Link MJ. Stereotactic radiosurgical salvage treatment for locally recurrent esthesioneuroblastoma. Neurosurgery 2013; 72:332-339.
41. Gordon KB, Char DH, Sagerman RH. Late effects of radiation on the eye and ocular adnexa. Int J Radiat Oncol Biol Phys 1995; 31:1123-1139.
42. Jeganathan VS, Wirth A, MacManus MP. Ocular risks from orbital and periorbital radiation therapy: A critical review. Int J Radiat Oncol Biol Phys 2011; 79:650-659.
43. Patel SH, Wang Z, Wong WW, Murad MH, Buckey CR, Mohammed K, Alahdab F, Altayar O, Nabhan M, Schild SE, Foote RL. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: A systematic review and meta-analysis. Lancet Oncol 2014; 15:1027-1038.